measurable residual disease

Personalizing Allogeneic Hematopoietic Cell Transplantation in Adult AML Using Measurable Residual Disease Testing

By MedXY 09/26/2026

Measurable residual disease (MRD) testing offers critical insights to tailor allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia, optimizing patient selection, conditioning intensity, and relapse surveillance to improve outcomes.

Hematology-Oncology news

Pre-Transplant KMT2A-PTD Measurable Residual Disease as a Prognostic Biomarker in Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation

By MedXY 09/10/2026

The presence of measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in AML significantly predicts poorer survival outcomes, highlighting its potential as a critical MRD biomarker for risk stratification.

Hematology-Oncology news Oncology

Real-World Impact of Post-Treatment Circulating Tumor DNA Monitoring in Large B-Cell Lymphoma Using an Immunoglobulin-Based Assay

By MedXY 08/25/2026

This study demonstrates that detection of circulating tumor DNA (ctDNA) after treatment in large B-cell lymphoma predicts progression-free survival, highlighting the clinical utility of a rapid immunoglobulin rearrangement-targeted assay for measurable residual disease assessment in real-world settings.

Hematology-Oncology news Oncology

Integrating Genetics and Measurable Residual Disease to Optimize Therapy in Philadelphia Chromosome-Negative Adult ALL

By MedXY 08/25/2026

Combining genetic risk stratification with measurable residual disease enables precise treatment allocation in adult Philadelphia chromosome-negative acute lymphoblastic leukemia, improving survival outcomes and guiding the use of allogeneic stem cell transplantation.

Hematology-Oncology news

Measurable Residual Disease as a Prognostic Biomarker in Frontline Azacitidine and Venetoclax-Treated AML: Insights from the French VENAURA Registry

By MedXY 07/20/2026

In AML patients receiving frontline azacitidine and venetoclax, achieving measurable residual disease negativity strongly predicts longer survival and lower relapse rates, overriding baseline risk factors, as shown in the French VENAURA registry.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

Next-Generation Sequencing MRD Detection Predicts Outcomes in AML Patients Undergoing Allogeneic Stem Cell Transplantation

By MedXY 05/30/2026

A low-cost NGS-based MRD test detected hidden AML cells before transplant and strongly predicted worse survival after allogeneic stem cell transplantation.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

MRD Does Not Consistently Predict PFS Across Modern CLL Trials: Why Surrogacy Depends on Therapy, Duration, and Sample Source

By MedXY 05/04/2026

A large meta-analysis shows MRD strongly predicts outcomes for individual patients with CLL, but is an inconsistent trial-level surrogate for progression-free survival, particularly with BTK inhibitor and venetoclax-based regimens.

Hematology-Oncology news Pediatrics

Genomic Fusion Breakpoints: A Breakthrough in Pediatric ALL MRD Monitoring

By MedXY 04/24/2026

A novel genomic fusion breakpoint (GFB)-based MRD monitoring approach demonstrates superior sensitivity and specificity in pediatric ALL, addressing limitations of current IG/TCR-based methods, particularly in ETV6::RUNX1- and MEF2D-rearranged subtypes.

Hematology-Oncology news Oncology

MRD-Guided Intensification: A Tailored Approach to First-Line Chronic Lymphocytic Leukaemia Treatment

By MedXY 12/19/2025

The HOVON 158/NEXT STEP phase 2 trial demonstrates that a measurable residual disease (MRD)-guided intensification strategy using ibrutinib and obinutuzumab significantly deepens remissions in first-line CLL patients who do not achieve deep responses with initial ibrutinib-venetoclax, while sparing early responders from additional toxicity.

Hematology-Oncology news

AlloHSCT in Adult Ph– ALL Treated with Pediatric-Inspired GIMEMA LAL1913: MRD Status at Transplant Drives Long-Term Outcomes

By MedXY 11/17/2025

Campus ALL real-world data show that pre-transplant MRD negativity after the pediatric-inspired GIMEMA LAL1913 protocol predicts substantially better 3‑year OS and DFS after alloHSCT; MRD-positive patients and those in CR2 fare markedly worse, while age >55 years does not preclude benefit.

Hematology-Oncology news

Tailoring Transplant Conditioning and Maintenance Therapy in FLT3-ITD AML: Insights on NPM1 Mutations and Measurable Residual Disease

By MedXY 11/04/2025

Posttransplant gilteritinib greatly benefits FLT3-ITD AML patients with NPM1 comutations, while myeloablative conditioning offers limited advantages over reduced-intensity conditioning in eradicating measurable residual disease.

Hematology-Oncology news Pediatrics

Molecular Monitoring of MRD in Pediatric AML with KMT2A::MLLT10: Prognostic Insights and Clinical Impact

By MedXY 10/14/2025

MRD monitoring by RT-qPCR in pediatric AML with KMT2A::MLLT10 fusion identifies patients at high risk despite morphologic remission, informing prognosis and guiding therapy.

Clinical Updates Hematology-Oncology news

Advancing Chronic Lymphocytic Leukemia Management: The Impact of Measurable Residual Disease-Guided Ibrutinib-Venetoclax Therapy

By MedXY 09/26/2025

Phase 3 trial data demonstrate that ibrutinib-venetoclax therapy achieves superior undetectable measurable residual disease rates and significantly prolonged progression-free survival compared with ibrutinib alone or FCR in chronic lymphocytic leukemia.

Clinical Updates Hematology-Oncology Medical News Specialties

MRD-Guided Consolidation Therapy in Newly Diagnosed Multiple Myeloma: Insights from the MIDAS Phase 3 Trial

By MedXY 07/31/2025

MRD-guided consolidation strategies in transplant-eligible multiple myeloma patients did not significantly improve deep remission rates over conventional approaches, questioning the clinical utility of MRD-adapted intensification.